Top Story

Baricitinib improves outcomes in patients with atopic dermatitis

September 14, 2017

Patients with moderate-to-severe atopic dermatitis experienced improvements in both clinical and patient-reported outcomes after treatment with Olumiant plus topical corticosteroids when compared with topical corticosteroids alone, according to phase 2 study data presented at the European Academy of Dermatology and Venereology Annual Congress in Geneva.

The analysis included 38 patients treated with 4-mg Olumiant (baricitinib, Eli Lilly) plus topical corticosteroids (TCS), 37 patients treated with 2-mg baricitinib plus TCS, and 49 patients treated with TCS alone. Patients received 16 weeks of treatment and were assessed for disease severity using the Eczema Area and Severity Index (EASI-50) score.

FDA News

FDA approves food label linking peanut introduction to reduced allergy risk

September 7, 2017
The FDA announced today that, for the first time, it has approved a petition for a qualified health claim linking early peanut introduction and the prevention of peanut…
In the Journals

Eucrisa demonstrated safety in atopic dermatitis

September 6, 2017
Encouraging safety outcomes were reported in a cohort of patients with atopic dermatitis who were treated with long-term Eucrisa. “Crisaborole is a…
In the Journals

Probiotics ineffective for preventing asthma, eczema in infants

August 29, 2017
The use of Lactobacillus rhamnosus GG, a probiotic, is unable to prevent asthma or eczema in children at 2 years of age when used in the first 6 months of life.
More Headlines »